|

Cladribine Clinical Trials

13 actively recruiting trials across 5 locations

▼ -1 trial since July 2026

Also known as: 2-CdA, 2CDA, CdA, Cladribina, Leustat +5 more

Pipeline

Phase 1: 1Phase 2: 7Phase 1/2: 4Phase 2/3: 1

Top Sponsors

  • M.D. Anderson Cancer Center8
  • University of Washington1
  • OHSU Knight Cancer Institute1
  • National Cancer Institute (NCI)1
  • Memorial Sloan Kettering Cancer Center1

Indications

  • Cancer13
  • Acute Myeloid Leukemia7
  • Refractory Acute Myeloid Leukemia4
  • Hairy Cell Leukemia3
  • Recurrent Acute Myeloid Leukemia3

Houston, Texas8 trials

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

University of Texas MD Anderson Cancer Center

Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

M D Anderson Cancer Center

Phase 2
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M D Anderson Cancer Center

Phase 1/2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

M D Anderson Cancer Center

Phase 2
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M D Anderson Cancer Center

Phase 2
Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

The University of Texas M. D. Anderson Cancer Center

Phase 1/2
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

M D Anderson Cancer Center

Phase 2/3
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

M D Anderson Cancer Center

Phase 2

Seattle, Washington2 trials

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Fred Hutch/University of Washington Cancer Consortium

Phase 1
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2

Miami, Florida1 trial

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

University of Miami Miller School of Medicine-Sylvester Cancer Center

Phase 2

Bethesda, Maryland1 trial

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

NCI - Center for Cancer Research

Phase 1/2

Boston, Massachusetts1 trial

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Dana Farber Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.